Section Arrow
Quote
TLX.NASDAQ
- Telix Pharmaceuticals Ltd.
Quotes are at least 15-min delayed:2026/10/18 21:42 EDT
Regular Hours
Last
 10.69
+0.12 (+1.14%)
Day High 
10.94 
Prev. Close
10.57 
1-M High
12.8 
Volume 
324.86K 
Bid
10.57
Ask
11
Day Low
10.66 
Open
10.92 
1-M Low
10.43 
Market Cap 
3.59B 
Currency 美元 
P/E 107.09 
%Yield -- 
10-SMA 10.9 
20-SMA 11.18 
50-SMA 11.52 
52-W High 13.1098 
52-W Low 6.28 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.10/0.04
Enterprise Value
4.04B
Balance Sheet
Book Value Per Share
1.44
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
803.79M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.465-0.695-16.71%-- 
TCRTAlaunos Therapeutics Inc.2.63+0.45+20.64%-- 
IBRXImmunityBio9.18-0.82-8.20%-- 
MRNAModerna218.01-18.49-7.82%-- 
SLSSELLAS Life Sciences Group9.98-1.36-11.99%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.